Inventiva SA
IVA4.010USD
-0.170-4.07%
Close 11/07, 16:00（ET）Quotes delayed by 15 min
0.00Market Cap
--P/E TTM
More Details of Inventiva SA Company
Inventiva SA is a France-based company engaged in the biotechnology sector. The Company focuses on the development of therapies in the area of oncology, fibrosis and rare diseases. The Company’s pipeline comprises a number of development programs, such as Clinical Pipeline, Preclinical Pipeline, AbbVie Collaboration and Boehringer-Ingelheim collaboration. Its drug candidates target at the treatment of non-alcoholic steatohepatitis (NASH), systemic sclerosis (SSc), various types of mucopolysaccharidosis (MPS), multiple myeloma, auto-immune disorders, as well as lung cancer, among others. In addition, the Company offers drug discovery services, ranging from target identification to preclinical nomination, in numerous areas, such as silico modelling, biology, screening, absorption, distribution, metabolism and excretion (ADME), pharmacology and histology.
Inventiva SA Info
Ticker SymbolIVA
Company nameInventiva SA
IPO dateFeb 15, 2017
CEOMr. Frederic Cren
Number of employees- -
Security typeOrdinary Share
Fiscal year-end- -
Address50 rue de Dijon
CityDAIX
Stock exchangeEuronext Paris
CountryFrance
Postal code21121
Phone33380447500
Websitehttps://inventivapharma.com/
Ticker SymbolIVA
IPO dateFeb 15, 2017
CEOMr. Frederic Cren
Company Executives of Inventiva SA
Name
Name/Position
Position
Shareholding
Change
Mr. Heinz Maeusli
Mr. Heinz Maeusli
Independent Director
Independent Director
--
--
Dr. Mark Pruzanski, M.D.
Dr. Mark Pruzanski, M.D.
Chairman of the Board
Chairman of the Board
--
--
Ms. Nathalie Harroy
Ms. Nathalie Harroy
Director - Human Resources
Director - Human Resources
--
--
Mr. Jean Volatier
Mr. Jean Volatier
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Martine Zimmerman
Ms. Martine Zimmerman
Independent Director
Independent Director
--
--
Dr. Srinivas (Srini) Akkaraju, M.D., Ph.D.
Dr. Srinivas (Srini) Akkaraju, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Annick Schwebig, M.D.
Dr. Annick Schwebig, M.D.
Independent Director
Independent Director
--
--
Andre Turenne
Andre Turenne
Independent Director
Independent Director
--
--
Dr. Jason Campagna, M.D., Ph.D.
Dr. Jason Campagna, M.D., Ph.D.
President - Research and Development, Chief Medical Officer
President - Research and Development, Chief Medical Officer
--
--
Ms. Pascaline Clerc
Ms. Pascaline Clerc
Executive Vice President - Strategy and Corporate Affairs
Executive Vice President - Strategy and Corporate Affairs
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Heinz Maeusli
Mr. Heinz Maeusli
Independent Director
Independent Director
--
--
Dr. Mark Pruzanski, M.D.
Dr. Mark Pruzanski, M.D.
Chairman of the Board
Chairman of the Board
--
--
Ms. Nathalie Harroy
Ms. Nathalie Harroy
Director - Human Resources
Director - Human Resources
--
--
Mr. Jean Volatier
Mr. Jean Volatier
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Martine Zimmerman
Ms. Martine Zimmerman
Independent Director
Independent Director
--
--
Dr. Srinivas (Srini) Akkaraju, M.D., Ph.D.
Dr. Srinivas (Srini) Akkaraju, M.D., Ph.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: 19 minutes ago
Updated: 19 minutes ago
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Yiheng Capital Management, L.P.
2.76%
New Enterprise Associates (NEA)
1.53%
BVF Partners L.P.
0.72%
Commonwealth Financial Network
0.07%
UBS Financial Services, Inc.
0.03%
Other
94.89%
Shareholders
Shareholders
Proportion
Yiheng Capital Management, L.P.
2.76%
New Enterprise Associates (NEA)
1.53%
BVF Partners L.P.
0.72%
Commonwealth Financial Network
0.07%
UBS Financial Services, Inc.
0.03%
Other
94.89%
Shareholder Types
Shareholders
Proportion
Investment Advisor
2.89%
Venture Capital
1.53%
Hedge Fund
0.74%
Investment Advisor/Hedge Fund
0.02%
Other
94.83%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
21
4.95M
5.18%
+27.37K
2025Q2
19
4.87M
5.09%
-661.07K
2025Q1
21
4.87M
5.09%
-959.14K
2024Q4
21
5.45M
6.26%
-698.93K
2024Q3
20
4.86M
9.25%
-1.29M
2024Q2
21
4.85M
9.24%
-1.47M
2024Q1
22
4.85M
9.31%
-1.45M
2023Q4
19
4.86M
9.33%
-1.43M
2023Q3
22
4.86M
11.53%
-1.45M
2023Q2
24
4.83M
11.47%
-1.47M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Yiheng Capital Management, L.P.
2.64M
2.76%
--
--
Jun 30, 2025
New Enterprise Associates (NEA)
1.46M
1.53%
--
--
Jun 30, 2025
BVF Partners L.P.
686.04K
0.72%
--
--
Jun 30, 2025
Commonwealth Financial Network
54.32K
0.06%
-169.00
-0.31%
Jun 30, 2025
UBS Financial Services, Inc.
27.45K
0.03%
+26.74K
+3776.84%
Jun 30, 2025
Wealth Enhancement Advisory Services, LLC
16.56K
0.02%
+5.84K
+54.53%
Jun 30, 2025
Citadel Advisors LLC
23.38K
0.02%
+23.38K
--
Jun 30, 2025
Creative Planning, Inc.
10.00K
0.01%
+10.00K
--
Jun 30, 2025
Geode Capital Management, L.L.C.
4.70K
0%
--
--
Aug 31, 2025
Morgan Stanley & Co. International Plc
2.10K
0%
+2.10K
--
Jun 30, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
